PTJ
BIVV

Paul Tudor Jones’s Bioverativ Inc. Common Stock BIVV Stock Holding History

Paul Tudor Jones’s Portfolio BIVV Stock Details BIVV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-203,015
Closed -$11.6M – 1411
2017
Q3 		$11.6M Buy
+203,015
New +$11.9M 0.3% 30
2017
Q2 		– Sell
-705,824
Closed -$38.4M – 1568
2017
Q1 		$38.4M Buy
+705,824
New +$34.8M 1.18% 9

Other funds holding BIVV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JIM
Jupiter Investment Management London, United Kingdom $6.26B AUM 13.19% 1-Year Est. Return

Paul Tudor Jones's BIVV Position: Q4 2017 in Review

Paul Tudor Jones sold out of Bioverativ Inc. Common Stock (BIVV) in Q4 2017, closing a stake of 203,015 shares — an estimated $11.6M sold.

Paul Tudor Jones first reported a position in BIVV in Q1 2017 and held it in 2 quarters. The position peaked at $38.4M in Q1 2017. 459 funds tracked by Wall St. Rank hold BIVV as of Q4 2017.

  • Paul Tudor Jones reported no remaining Bioverativ Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
  • Paul Tudor Jones sold 203,015 Bioverativ Inc. Common Stock shares in Q4 2017, an estimated $11.6M.
  • Paul Tudor Jones first reported a position in Bioverativ Inc. Common Stock in Q1 2017 and held it in 2 quarters.
  • Paul Tudor Jones's Bioverativ Inc. Common Stock position peaked at $38.4M in Q1 2017.
  • 459 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q4 2017.

Based on Tudor Investment Corp's 13F filing for Q4 2017, filed 14 Feb 2018.